Search research articles
Contact Us
Filters
Showing results (1-10 of 113) with videos related to
Page
of 12
Sort By:
Current Oncology Reports
|
December 21, 2000
Differentiating agents in pediatric malignancies: retinoids in neuroblastoma
C P Reynolds
Progress in Clinical and Biological Research
|
January 1, 1985
Modulation of cell surface antigens accompanies morphological differentiation of human neuroblastoma cell lines
C P Reynolds, J Maples
Journal of Pediatric Hematology/Oncology
|
April 18, 2001
Detection of minimal residual disease in bone marrow during or after therapy as a prognostic marker for high-risk neuroblastoma
C P Reynolds, R C Seeger
Hematology/Oncology Clinics of North America
|
January 5, 2002
Retinoid therapy of childhood cancer
C P Reynolds, R S Lemons
Pediatric Clinics of North America
|
April 1, 1991
Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation
R C Seeger, C P Reynolds
Bone Marrow Transplantation
|
August 22, 2002
Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy
C P Anderson, C P Reynolds
Cancer Chemotherapy and Pharmacology
|
January 1, 1989
Determination of subcutaneous tumor size in athymic (nude) mice
M M Tomayko, C P Reynolds
Journal of Biochemical and Biophysical Methods
|
June 1, 1987
Automation of protein assays with a microcomputer interfaced to a spectrophotometer
S M Ross, C P Reynolds
Diagnostic and Clinical Immunology
|
January 1, 1987
Monoclonal antibody recognizing a human neuroblastoma-associated antigen
R G Smith, C P Reynolds
British Journal of Cancer
|
October 12, 2000
Is there a role for retinoids to treat minimal residual disease in neuroblastoma?
K K Matthay, C P Reynolds
Page
of 12
Search research articles
Search
Showing results (1-10 of 113) with videos related to
Sort By:
Page
of 12
Current Oncology Reports
|
December 21, 2000
Differentiating agents in pediatric malignancies: retinoids in neuroblastoma
C P Reynolds
Progress in Clinical and Biological Research
|
January 1, 1985
Modulation of cell surface antigens accompanies morphological differentiation of human neuroblastoma cell lines
C P Reynolds, J Maples
Journal of Pediatric Hematology/Oncology
|
April 18, 2001
Detection of minimal residual disease in bone marrow during or after therapy as a prognostic marker for high-risk neuroblastoma
C P Reynolds, R C Seeger
Hematology/Oncology Clinics of North America
|
January 5, 2002
Retinoid therapy of childhood cancer
C P Reynolds, R S Lemons
Pediatric Clinics of North America
|
April 1, 1991
Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation
R C Seeger, C P Reynolds
Bone Marrow Transplantation
|
August 22, 2002
Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy
C P Anderson, C P Reynolds
Cancer Chemotherapy and Pharmacology
|
January 1, 1989
Determination of subcutaneous tumor size in athymic (nude) mice
M M Tomayko, C P Reynolds
Journal of Biochemical and Biophysical Methods
|
June 1, 1987
Automation of protein assays with a microcomputer interfaced to a spectrophotometer
S M Ross, C P Reynolds
Diagnostic and Clinical Immunology
|
January 1, 1987
Monoclonal antibody recognizing a human neuroblastoma-associated antigen
R G Smith, C P Reynolds
British Journal of Cancer
|
October 12, 2000
Is there a role for retinoids to treat minimal residual disease in neuroblastoma?
K K Matthay, C P Reynolds
Page
of 12